BioSpace News Archive

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company today announced business updates and financial results for the first quarter ended March 31, 2021.

Dynatronics Corporation, a leading manufacturer of athletic training, physical therapy, and rehabilitation products, announced financial results for its third quarter of fiscal year 2021 for the period ended March 31, 2021.

– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency (“EMA”) in the Company’s Pediatric Investigation Plan (“PIP”) – Patient enrollment on track to start this quarter – Planned completion of pivotal Phase 3 study expected in Q3 2022

Expanded capabilities in company’s Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges

BioEquity Europe Digital Oxford Global’s Online Drug Discovery Week Jefferies Virtual Healthcare Conference 2021 Precision in Drug Discovery & Preclinical Virtual Summit European Hematology Association (EHA) 2021 Congress BIO International Convention 2021

Selecta Biosciences today reported financial results for the first quarter ended March 31, 2021 and provided a business update.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences: Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 11:35am ET Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30pm ET

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions and to raise awareness of the Merus eNRGy clinical trial of its bispecific antibody

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that medical and clinical leader Dennis D. Kim, MD, MBA, is joining the company as Chief Medical Officer.

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA,